The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Status:
Recruiting
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
This is a signle-arm, multi-center, open-lable, phase II study. The objective is to evaluate
the effectiveness and safety of tislelizumab + oxaliplatin + capecitabine + PLD in the
neoadjuvant treatment of resectable gastric adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine